Duality Biologics Signs Exclusive Option Agreement with GSK for ADC Candidate DB-1324 in Gastrointestinal Cancer

 Duality Biologics ("DualityBio"), a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjuga...

December 04, 2024 | Wednesday | News
Amarna Therapeutics Forms Strategic Partnership with NorthX Biologics to Advance Gene Therapy Development

Amarna Therapeutics, (“Amarna” or “the Company”), a privately held biotechnology company specializing in transformative gene therap...

December 04, 2024 | Wednesday | News
Merck’s Sacituzumab Tirumotecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthroug...

December 04, 2024 | Wednesday | News
Smart Immune and CELLforCURE Partner to Scale SMART101 Production for Advanced Cell Therapy Trials

Smart Immune, a clinical-stage biotechnology company, and CELLforCURE by SEQENS, a Contract  Development and Manufacturing Organization (CDMO) for Adv...

December 03, 2024 | Tuesday | News
Jasper Therapeutics Doses First Patient in Phase 1b/2a ETESIAN Study of Briquilimab for Allergic Asthma

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy t...

December 03, 2024 | Tuesday | News
Kelun-Biotech's Sacituzumab Tirumotecan (Sac-TMT) Gains Marketing Approval for Advanced TNBC in China

The competition among three TROP2 antibody-drug conjugates is entering a new stage as Kelun-Biotech’s Merck & Co.-partnered sacituzumab...

December 02, 2024 | Monday | News
Ascentage Pharma’s Olverembatinib Gains Expanded Inclusion in China’s 2024 National Reimbursement Drug List

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet med...

November 29, 2024 | Friday | News
European Commission Approves TEVIMBRA® for First-Line Treatment of Esophageal and Gastric Cancers

 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines, announced ...

November 28, 2024 | Thursday | News
Eisai and Biogen Launch LEQEMBI® for Early Alzheimer's Treatment in South Korea

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...

November 28, 2024 | Thursday | News
Novartis Announces European Commission Approval of Kisqali® (ribociclib) for Adjuvant Treatment of High-Risk HR+/HER2- Early Breast Cancer

Novartis announced that the European Commission (EC) has approved Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the ad...

November 28, 2024 | Thursday | News
Roche to Acquire Poseida Therapeutics in Strategic Move to Advance Off-the-Shelf CAR-T Cell Therapies

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. (“Poseida&r...

November 27, 2024 | Wednesday | News
SCG Cell Thearapy Presents Promising Phase 1 Data for SCG101, a First-in-Class HBV-Specific TCR-T Therapy

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company focused on developing innovative immunotherapies for infectious diseases and associa...

November 25, 2024 | Monday | News
Kedrion Biopharma's Bolognana Facility FDA-Approved to Manufacture RYPLAZIM® for PLGD-1 Treatment

 Kedrion Biopharma Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved the company's manufacturing facility in B...

November 22, 2024 | Friday | News
Avirmax Biopharma Doses First Patient in Phase I/IIa Trial of ABI-110, Pioneering Gene Therapy for Wet AMD and PCV

Avirmax Biopharma, Inc., a leader in the development of innovative gene therapies, announced that the first patient has been successfully dosed in the Phas...

November 22, 2024 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close